牲畜疫苗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球牲畜疫苗市场规模达64亿美元，预计到2034年将以7.1%的复合年增长率增长，达到126亿美元，这得益于动物健康意识的提升、工业化养殖的扩张以及疫苗技术的进步。这一成长趋势主要归因于农民对疾病预防的重视程度不断提高，以及对免疫相关经济效益的认识日益加深。随着畜牧业的工业化程度不断提高，对综合疾病管理策略的需求也日益增强。科技创新进一步推动了高效疫苗的研发，增强了动物健康水平，并提高了农场的生产力。全球疾病疫情频繁，预防措施的紧迫性日益增强，尤其对于仍高度脆弱的家禽。全球粮食安全越来越依赖畜牧业的生产力，这使得动物健康成为农业永续发展的关键因素。此外，疾病和死亡损失的减少直接支持了农业经营的经济可行性，尤其是在高密度养殖环境下。市场继续受益于有利的政府政策、产业合作以及对动物保健基础设施的投资增加。

牛、猪、家禽、水产养殖物种以及绵羊和山羊等牲畜是农业经济的核心，其用途广泛，包括粮食生产、纤维生产和劳动力。疫苗接种被广泛认为是保障动物健康和减少传染病经济影响的重要工具。 2024年，家禽业占据了最大的市场份额，创造了24亿美元的收入，预计到2034年将达到45亿美元，复合年增长率为6.5%。家禽仍然是全球主要饮食来源，这主要是因为与其他牲畜相比，家禽的生产成本更低、週转速度更快。家禽产品需求的成长，尤其是在快速发展地区，加速了大规模疫苗接种实践的采用。该产业面临病毒和细菌疫情的持续威胁，凸显了强有力的疫苗接种计画的重要性。

在疫苗类型中，减毒活疫苗占据市场主导地位，2024 年的市占率为 45.9%。预计到 2034 年，该领域将保持领先地位，复合年增长率为 6.7%。这些疫苗非常有效，因为它们模拟自然感染，只需较少剂量即可提供强效持久的免疫力。它们常用于治疗严重的牲畜疾病，使其成为大规模动物健康管理的首选解决方案。这些疫苗也以提供更快的免疫反应而闻名，这在疾病可能迅速传播的密集养殖环境中至关重要。

在给药途径方面，口服疫苗因其便利性和在大规模生产中的有效性而备受青睐。预计到2034年，该领域的市值将达到71亿美元，复合年增长率将达到6.8%。口服疫苗为动物免疫提供了一种轻鬆便捷的方式，尤其是在家禽、猪和牛养殖领域。口服疫苗可以透过饲料或饮水给药，减少了操作，从而最大限度地降低了受伤风险，并确保了更高的畜群依从性。疫苗製剂技术的进步提高了口服疫苗的稳定性和有效性，使其越来越适合广泛应用。

在应用方面，病毒感染疫苗占据了相当大的市场份额，预计到2034年将达到68亿美元，复合年增长率为7.2%。反覆爆发的病毒疫情持续对畜牧业构成重大挑战，无论是在动物健康方面或经济方面。这些疾病显着降低了产量，迫使农民采取有效的预防措施。疫苗製造商持续的研发投入预计将推动该领域的创新，提高病毒疫苗的有效性和可近性。

在分销方面，兽医院药局占了最大的收入份额，2024 年达 33 亿美元，预计到 2034 年将达到 64 亿美元，复合年增长率为 6.9%。这些机构因其全面的护理服务而备受青睐，包括诊断、咨询和即时疫苗接种。兽医院护理网络的扩展，尤其是在新兴市场，正在促进动物医疗保健的可近性。兽医院结构化的配送系统可确保及时接种疫苗，减少错失良机，并提高整体效果。

美国引领北美牲畜疫苗市场，2024年估值达24亿美元。其领先地位得益于其先进的动物保健体系、高昂的兽医支出以及政府对预防性牲畜保健的持续支持。疾病的流行持续推动疫苗接种需求，从而推动市场向前发展。

硕腾、默克动物保健、勃林格殷格翰、礼来和诗华等主要企业合计占据全球约45%的市场。他们的主导地位得益于广泛的产品线、强大的全球分销网络以及对下一代疫苗开发的战略投资。牲畜疫苗产业保持中等程度的整合，这些领导者引领动物保健解决方案的创新、效率和永续性。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 牲畜疾病发生率上升
    • 农民对疫苗接种益处的认识不断提高。
    • 政府支持动物健康和食品安全的措施和政策。
    • 技术进步促进了更有效疫苗的开发
  • 产业陷阱与挑战
    • 疫苗研发和分发成本高昂
    • 监管障碍可能会延迟产品审批和市场进入。
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供给侧影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 管道分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 家禽
• 牛
• 猪
• 水产养殖
• 绵羊和山羊

第六章：市场估计与预测：按疫苗类型，2021 - 2034 年

• 主要趋势
• 减毒活疫苗
• 结合疫苗
• 灭活疫苗
• 重组疫苗
• 其他疫苗类型

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 父母
• 其他给药途径

第八章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 细菌感染
• 病毒感染
• 寄生虫感染
• 其他应用

第九章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 兽医院药房
• 零售药局
• 电子商务

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Biogenesis Bago
• Bioveta
• Boehringer Ingelheim
• Ceva
• Elanco
• HIPRA
• Indian Immunologicals
• Merck Animal Health
• Neogen
• Phibro Animal Health
• SAN VET
• Vaxxinova
• Venkys
• Virbac
• Zoetis

The Global Livestock Vaccines Market was valued at USD 6.4 billion in 2024 and is estimated to grow at a CAGR of 7.1% to reach USD 12.6 billion by 2034, driven by increased awareness of animal health, the expansion of industrial farming, and advancements in vaccine technology. This rising trend is largely attributed to the heightened focus on disease prevention among farmers and a growing understanding of the economic advantages linked to immunization. As livestock farming becomes more industrialized, the need for comprehensive disease management strategies grows stronger. Technological innovation has further enabled the development of highly effective vaccines, strengthening animal health outcomes and improving productivity across farms. The emergence of frequent disease outbreaks globally has led to increased urgency around preventive measures, especially for poultry, which remains a highly vulnerable category. Global food security is increasingly reliant on livestock productivity, making animal health a critical aspect of agricultural sustainability. Moreover, the reduction in losses due to illness and mortality directly supports the economic viability of farming operations, especially in high-density production settings. The market continues to benefit from favorable government policies, industry collaborations, and increased investments in animal healthcare infrastructure.

Livestock animals such as cattle, swine, poultry, aquaculture species, and sheep and goats are central to the agricultural economy, serving various purposes including food production, fiber, and labor. Vaccination is widely recognized as an essential tool for safeguarding animal health and reducing the economic impact of infectious diseases. In 2024, the poultry segment held the largest market share, generating USD 2.4 billion in revenue, and is projected to reach USD 4.5 billion by 2034, growing at a CAGR of 6.5%. Poultry remains a global dietary staple, largely due to its lower production costs and faster turnover compared to other livestock. Increased demand for poultry products, particularly in rapidly developing regions, has accelerated the adoption of mass vaccination practices. The industry faces ongoing threats from viral and bacterial outbreaks, which have emphasized the importance of robust vaccination programs.

Among vaccine types, attenuated live vaccines dominate the market, holding a 45.9% share in 2024. This segment is expected to maintain its leading position through 2034 with a CAGR of 6.7%. These vaccines are highly effective because they mimic natural infections, providing strong and long-lasting immunity with fewer doses. Their use is common in addressing serious livestock diseases, making them a preferred solution for large-scale animal health management. These vaccines are also known for providing quicker immune responses, an essential factor in intensive farming setups where disease can spread rapidly.

Regarding administration routes, the oral segment is gaining significant traction due to its convenience and effectiveness in large-scale operations. Valued at USD 7.1 billion by 2034, this segment is projected to grow at a CAGR of 6.8%. Oral vaccines offer a stress-free way to immunize animals, especially in poultry, swine, and cattle sectors. Their ability to be administered through feed or water reduces handling, thereby minimizing injury risks and ensuring higher compliance across herds. Technological progress in vaccine formulation has improved the stability and efficiency of oral vaccines, making them increasingly suitable for widespread use.

In terms of applications, viral infection vaccines hold a substantial share of the market, anticipated to reach USD 6.8 billion by 2034, with a CAGR of 7.2%. Recurring viral outbreaks continue to pose major challenges to the livestock industry, both in terms of animal health and economic impact. These diseases significantly reduce production yields, compelling farmers to adopt effective preventive solutions. The ongoing investment in research and development by vaccine manufacturers is expected to drive innovation in this segment, improving the efficacy and accessibility of viral vaccines.

When it comes to distribution, veterinary hospital pharmacies accounted for the largest revenue share of USD 3.3 billion in 2024 and are forecasted to hit USD 6.4 billion by 2034, growing at a CAGR of 6.9%. These facilities are preferred for their comprehensive care offerings, including diagnostics, consultations, and immediate vaccine administration. The expansion of veterinary care networks, especially in emerging markets, is contributing to better access to animal healthcare. The structured delivery system in veterinary hospitals ensures timely vaccination, reducing missed opportunities and increasing overall effectiveness.

The United States leads the North American livestock vaccines market, achieving a valuation of USD 2.4 billion in 2024. This leadership is supported by an advanced animal healthcare framework, high veterinary expenditure, and consistent government support for preventive livestock care. Disease prevalence continues to drive demand for vaccination, pushing the market forward.

Key players such as Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, and Ceva collectively hold around 45% of the global market. Their dominance is attributed to broad product lines, strong global distribution networks, and strategic investments in next-generation vaccine development. The livestock vaccines industry remains moderately consolidated, with these leaders setting the pace for innovation, efficiency, and sustainability in animal health solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of livestock diseases
    • 3.2.1.2 Growing awareness among farmers about the benefits of vaccination.
    • 3.2.1.3 Government initiatives and policies supporting animal health and food security.
    • 3.2.1.4 Technological advancements leading to the development of more effective vaccines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with vaccine development and distribution
    • 3.2.2.2 Regulatory hurdles that can delay product approvals and market entry.
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Poultry
• 5.3 Cattle
• 5.4 Swine
• 5.5 Aquaculture
• 5.6 Sheep and goats

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Attenuated live vaccine
• 6.3 Conjugate vaccine
• 6.4 Inactivated vaccine
• 6.5 Recombinant vaccine
• 6.6 Other vaccine types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parentral
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Bacterial infections
• 8.3 Viral infections
• 8.4 Parasitic infections
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Biogenesis Bago
• 11.2 Bioveta
• 11.3 Boehringer Ingelheim
• 11.4 Ceva
• 11.5 Elanco
• 11.6 HIPRA
• 11.7 Indian Immunologicals
• 11.8 Merck Animal Health
• 11.9 Neogen
• 11.10 Phibro Animal Health
• 11.11 SAN VET
• 11.12 Vaxxinova
• 11.13 Venkys
• 11.14 Virbac
• 11.15 Zoetis